Hong Kong's regulatory reforms mostly welcomed by pharma
This article was originally published in Scrip
The pharmaceutical industry in Hong Kong has generally welcomed a set of far-reaching recommendations to come out of an official review of pharmaceutical regulation in the territory, although it has lingering concerns about their full implementation.
You may also be interested in...
European industry federation says first practical application of Japan’s cost effectiveness assessment system has highlighted a number of problems for both the scheme and its members, and calls for changes.
Takeda continued to prove largely resistant to the business impact of the pandemic last fiscal year, when it made solid progress and exceeded a number of post-Shire targets. R&D spending is set to ramp-up as the Japanese firm progresses its 'Wave 1' pipeline to market.
German mRNA specialist choses Singapore as its first regional hub in Asia Pacific, where it also plans to build a manufacturing site to support the global supply of both vaccines and therapeutics and a regional “rapid response” capability for future pandemics.